PARADIGM trial

Anteris Advances DurAVR THV With IDE and Trial Readiness

MINNEAPOLIS & BRISBANE, May 13, 2025—Anteris Technologies Global Corp. announced its first-quarter 2025 results, revealing significant progress across clinical...

By cGxPwire Editor
November 13, 2025

MedTech

FDA Clears Anteris PARADIGM Trial for DurAVR Heart Valve

Minneapolis, USA, and Brisbane, Australia – November 3, 2025 Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) has announced...

By cGxPwire Editor
November 4, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

PARADIGM trial

Anteris Advances DurAVR THV With IDE and Trial Readiness

FDA Clears Anteris PARADIGM Trial for DurAVR Heart Valve